Inflammatory bowel disease

Oral Diseases

Volumn 18, Issue 1, 2012, Pages 1-15

  Boirivant, M ^a   Cossu, A ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Inflammatory bowel disease; Management; Pathogenesis; Therapy

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN A; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MERCAPTOPURINE; MESALAZINE; STAT3 PROTEIN; STEROID; TOCILIZUMAB; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BODY MASS; CLINICAL FEATURE; COLITIS; CROHN DISEASE; ENTERITIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MOUTH CAVITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROCTITIS; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MOUTH DISEASES; REMISSION INDUCTION;

EID: 84155165036     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01811.x     Document Type: Review

References (203)

1. Abraham C, Cho JH (2006). Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 12: 641-650.
2. Abraham C, Cho JH (2009). Inflammatory bowel disease. N Engl J Med 361: 2066-2078.
3. Ahern PP, Izcue A, Maloy KJ, Powrie F (2008). The interleukin-23 axis in intestinal inflammation. Immunol Rev 226: 147-159.
4. Ahern PP, Schiering C, Buonocore S et al (2010). Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33: 279-288.
5. Ahmad T, Armuzzi A, Bunce M et al (2002). The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122: 854-866.
6. Alvarez-Lobos M, Arostegui JI, Sans M et al (2005). Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 242: 693-700.
7. Angriman I, Scarpa M, Ruffolo C et al (2008). Double contrast small-bowel radiography in the preoperative assessment of Crohn's disease: is it still useful? Surg Today 38: 700-704.
8. Artis D (2008). Epithelial-cell recognition of commensal flora and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8: 411-421.
9. Atreya R, Mudter J, Finotto S et al (2000). Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 6: 583-588.
10. Baert F, Moortgat L, van Assche G et al (2010). Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138: 463-468.
11. Barnes MJ, Powrie F (2009). Regulatory T cells reinforce intestinal homeostasis. Immunity 31: 401-411.
12. Barrett JC, Hansoul S, Nicolae DL et al (2008). Genome wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962.
13. Baumgart DC, Carding SR (2007). Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640.
14. Baumgart DC, Sandborn WJ (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
15. Beaugerie L, Brousse N, Bouvier AM et al (2009). Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617-1625.
16. Benevento G, Avellini C, Terrosu G, Geraci M, Lodolo I, Sorrentino D (2010). Diagnosis and assessment of Crohn's disease: the present and the future. Expert Rev Gastroenterol Hepatol 4: 757-766.
17. Bernstein CN, Boult IF, Greenberg HM, van der Putten W, Duffy G, Grahame GR (1997). A prospective randomized comparison between small bowel enteroclysis and small bowel follow-through in Crohn's disease. Gastroenterology 113: 390-398.
18. Biancone L, Michetti P, Travis S et al (2008). European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohn's Colitis 2: 63-92.
19. Blonski W, Lichtenstein GR (2006). Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 22: 30-43.
20. Boh EE, al-Smadi RM (2002). Cutaneous manifestations of gastrointestinal diseases. Dermatol Clin 20: 533-546.
21. Boirivant M, Pica R, De Maria R, Testi R, Pallone F, Strober W (1996). Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis. J Clin Invest 98: 2616-2622.
22. Boirivant M, Marini M, Di Felice G et al (1999). Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116: 557-565.
23. Boirivant M, Pallone F, Di Giacinto C et al (2006). Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis. Gastroenterology 131: 1786-1798.
24. Bouma G, Strober W (2003). The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3: 521-533.
25. Breese EJ, Michie CA, Nicholls SW et al (1994). Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466.
26. Canavan C, Abrams KR, Mayberry J (2006). Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 23: 1097-1104.
27. Canavan C, Abrams KR, Mayberry J (2007). Meta-analysis: mortality in Crohn's disease. Aliment Pharmacol Ther 25: 861-870.
28. Carter MJ, Lobo AJ, Travis SP, IBD Section BSoG (2004). Guidelines for the management of inflammatory bowel disease in adults. Gut 53(Suppl 5): V1-V16.
29. Chan SW, Scully C, Prime SS, Eveson J (1991). Pyostomatitis vegetans: oral manifestation of ulcerative colitis. Oral Surg Oral Med Oral Pathol 72: 689-692.
30. Chen W, Jin W, Hardegen N et al (2003). Conversion of peripheral CD4+ CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886.
31. Cho JH, Weaver CT (2007). The genetics of inflammatory bowel disease. Gastroenterology 133: 1327-1339.
32. Cleynen I, Mahachie John JM, Henckaerts L et al (2010). Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. PLoS ONE 5: e12952.
33. Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004). The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19-31.
34. Coombes JL, Powrie F (2008). Dendritic cell in intestinal immune regulation. Nat Rev Immunol 8: 435-446.
35. Coombes JL, Siddiqui KR, Arancibia-Càrcamo CV et al (2007). A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-b and retinoic acid dependent mechanism. J Exp Med 204: 1757-1764.
36. Cooney R, Baker J, Brain O et al (2010). NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16: 90-97.
37. Cosnes J (2004). Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 18: 481-496.
38. Cosnes J, Cattan S, Blain A et al (2002). Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 8: 244-250.
39. Crome SQ, Wang AY, Levings MK (2009). Translational mini-review series on Th17 Cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 159: 109-119.
40. Cuthbert AP, Fisher SA, Mirza MM et al (2002). The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122: 867-874.
41. Deknuydt F, Bioley G, Valmori D, Ayyoub M (2009). IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 131: 298-307.
42. D'Haens GR (2007). Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732.
43. D'Haens GR (2010). Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 7: 86-92.
44. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P (1998). Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114: 262-267.
45. D'Haens G, Baert F, van Assche G et al (2008). Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667.
46. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC (2009). Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 4: CD006873.
47. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde KH (1995). Tolerance exists towards resident intestinal flora but is broken in active inflammatory disease (IBD). Clin Exp Immunol 102: 448-455.
48. Duchmann R, Marker-Hermann E, Meyer zum Buschenfelde KH (1996). Bacteria-specific T-cell clones are selective in their reactivity towards different enterobacteria or H. pylori and increased in inflammatory bowel disease. Scand J Immunol 44: 71-79.
49. Duerkop BA, Vaishnava S, Hooper LV (2009). Immune responses to the microbiota at the intestinal mucosal surface. Immunity 31: 368-376.
50. Duerr RH, Taylor KD, Brant SR et al (2006). A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463.
51. Eaden JA, Abrams KR, Mayberry JF (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535.
52. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP (2004). Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a meta-analysis. Am J Gastroenterol 99: 2393-2404.
53. Ekbom A, Helmick C, Zack M, Adami HO (1990). Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233.
54. Elphick DA, Mahida YR (2005). Paneth cells: their role in innate immunity and inflammatory disease. Gut 54: 1802-1809.
55. Fatahzadeh M (2009). Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 108: e1-e10.
56. Feuerer M, Hill JA, Mathis D, Benoist C (2009). Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 10: 689-695.
57. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104: 13780-13785.
58. Friedman S, Blumberg R (2008). Inflammatory bowel disease. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL et al, eds Harrison's Principles of Internal Medicine, 17th edn. McGraw Hill: New York, pp. 1777-1789.
59. Fujino S, Andoh A, Bamba S et al (2003). Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
60. Fuss IJ, Neurath M, Boirivant M et al (1996). Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157: 1261-1270.
61. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W (1999). Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 117: 1078-1088.
62. Fuss IJ, Heller F, Boirivant M et al (2004). Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 113: 1490-1497.
63. Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G (1999). Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease. Gut 44: 112-117.
64. Gasche C, Scholmerich J, Brynskov J et al (2000). A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6: 8-15.
65. Gisbert JP, Gomollón F (2008). Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103: 1783-1800.
66. Gisbert JP, González-Lama Y, Maté J (2007). Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 102: 1518-1527.
67. Gore RM, Balthazar EJ, Ghahremani GG, Miller FH (1996). CT features of ulcerative colitis and Crohn's disease. Am J Roentgenol 167: 3-15.
68. Greenberg MS, Pinto A (2003). Etiology and management of recurrent aphtous stomatitis. Curr Infect Dis Rep 5: 194-198.
69. Greenstein AJ, Lachman P, Sachar DB et al (1988). Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 29: 588-592.
70. Griffiths AM (2004). Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 18: 509-523.
71. Guagnozzi D, Cossu A, Viscido A et al (2004). Acute intestinal obstruction and NOD2/CARD15 mutations among Italian Crohn's disease patients. Eur Rev Med Pharmacol Sci 8: 179-185.
72. Gupta RB, Harpaz N, Itzkowitz S et al (2007). Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133: 1099-1105.
73. Hampe J, Grebe J, Nikolaus S et al (2002). Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359: 1661-1665.
74. Hampe J, Franke A, Rosenstiel P et al (2007). A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39: 207-211.
75. Hanauer SB, Sandborn W, Practice Parameters Committee of the American College of Gastroenterology (2001). Management of Crohn's disease in adults. Am J Gastroenterol 96: 635-643.
76. Hansen LS, Silverman S Jr, Daniels TE (1983). The differential diagnosis of pyostomatitis vegetans and its relation to bowel disease. Oral Surg Oral Med Oral Pathol 55: 363-373.
77. Harrington LE, Hatton RD, Mangan PR et al (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132.
78. Harty S, Fleming P, Rowland M et al (2005). A prospective study of the oral manifestations of Crohn's disease. Clin Gastroenterol Hepatol 3: 886-891.
79. Hedl M, Li J, Cho JH, Abraham C (2007). Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci USA 104: 19440-19445.
80. Hellers G, Bergstrand O, Ewerth S, Holmström B (1980). Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 21: 525-527.
81. Homer CR, Richmond AL, Rebert NA, Achkar JP, McDonald C (2010). ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology 139: 1630-1641.
82. Hussey S, Rowland M, Fleming P (2007). Outcomes of oral Crohn's disease in children. Can J Gastroenterol 21: 5211.
83. Ina K, Itoh J, Fukushima K et al (1999). Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 163: 1081-1090.
84. Isaacs KL, Sartor RB, Haskill S (1992). Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 103: 1587-1595.
85. Ito H (2005). Treatment of Crohn's disease with anti-IL-6 receptor antibody. J Gastroenterol 40(Suppl. 16): 32-34.
86. Ito T, Hanabuchi S, Wang YH et al (2008). Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28: 870-880.
87. Iwasaki A, Medzhitov R (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol 5: 987-995.
88. Izcue A, Hue S, Buonocore S et al (2008). Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 28: 559-570.
89. Jess T, Loftus EV Jr, Velayos FS et al (2006). Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 130: 1039-1046.
90. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Márquez G, Agace W (2003). Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 198: 963-969.
91. Judge TA, Lichtenstein GR (2003). Inflammatory bowel disease. In: Friedman SL, McQuaid KR, Grendell JH, eds Current Diagnosis and Treatment in Gastroenterology, 2th Edn. Lange Medical Books/Mc Graw-Hill: New York, pp. 108-130.
92. Katsanos KH, Vermeire S, Christodoulou DK et al (2007). Dysplasia and cancer in inflammatory bowel disease 10years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 75: 113-121.
93. Kobayashi T, Okamoto S, Hisamatsu T et al (2008). IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57: 1682-1689.
94. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I (2008). Human CD25high Foxp3 positive regulatory T cells differentiate into IL-17-producing cells. Blood 112: 2340-2352.
95. Kornbluth A, Sachar DB (2004). Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 99: 1371-1385.
96. Lakatos PL, Lakatos L (2008). Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacother 9: 741-749.
97. Lampen A, Meyer S, Arnhold T, Nau H (2000). Metabolism of vitamin A and its active metabolite all-trans-retinoic acid in small intestinal enterocytes. J Pharmacol Exp Ther 295: 979-985.
98. Langholz E (2010). Current trends in inflammatory bowel disease: the natural history. Ther Adv Gastroenterol 3: 77-86.
99. Langholz E, Munkholm P, Davidsen M, Binder V (1994). Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107: 3-11.
100. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V (1996). Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 31: 260-266.
101. Larson DW, Pemberton JH (2004). Current concepts and controversies in surgery for IBD. Gastroenterology 126: 1611-1619.
102. Lesage S, Zouali H, Cézard JP et al (2002). CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 70: 845-857.
103. Levine B, Deretic V (2007). Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol 7: 767-777.
104. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological Association (2006). American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130: 940-987.
105. Lisciandrano D, Ranzi T, Carrassi A et al (1996). Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 91: 7-10.
106. Loftus EV Jr (2004). Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology 126: 1504-1517.
107. Loftus EV Jr, Schemed P, Sandborn WJ (2002). The epidemiology and natural history of Crohn's disease in population based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 16: 51-60.
108. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J (2001). Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49: 777-782.
109. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A (1990). Tumour necrosis factor alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81: 301-305.
110. Manel N, Unutmaz D, Littman DR (2008). The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9: 641-649.
111. Mannon PJ, Fuss IJ, Mayer L et al (2004). Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351: 2069-2079.
112. Marie JC, Letterio JJ, Gavin M, Rudensky AY (2005). TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+ CD25+ regulatory T cells. J Exp Med 201: 1061-1067.
113. Marks DJ, Segal AW (2008). Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol 214: 260-266.
114. Maul J, Loddenkemper C, Mundt P et al (2005). Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 128: 1868-1878.
115. Maynard CL, Weaver CT (2008). Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 226: 219-233.
116. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HV, MacDonald TT (2001). Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-609.
117. Mora JR, Bono MR, Manjunath N et al (2003). Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424: 88-93.
118. Mowat AMcI (2003). The anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 3: 331-341.
119. Munkholm P, Langholz E, Davidsen M, Binder V (1993). Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 105: 1716-1723.
120. Munkholm P, Langholz E, Davidsen M, Binder V (1995). Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30: 699-706.
121. Murai M, Krause P, Cheroutre H, Kronenberg M (2010). Regulatory T-cell stability and plasticity in mucosal and systemic immune systems. Mucosal Immunol 3: 443-449.
122. Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L (2008). Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature 455: 396-400.
123. Netea MG, Kullberg BJ, de Jong DJ et al (2004). NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. J Immunol 34: 2052-2059.
124. Neurath MF, Fuss IJ, Kelsall BL, Stüber E, Strober W (1995). Antibodies to IL-12 abrogate established experimental colitis in mice. J Exp Med 182: 1281-1290.
125. Neville BW, Smith SE, Maize JC, Laden SA, Denton WT (1985). Pyostomatitis vegetans. Am J Dermatopathol 7: 69-77.
126. Noguchi D, Wakita D, Tajima M et al (2007). Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int Immunol 19: 1431-1440.
127. Oppmann B, Lesley R, Blom B et al (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biologic activities similar as well as distinct from IL-12. Immunity 13: 715-725.
128. Palamaras I, El-Jabbour J, Pietropaolo N et al (2008). Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol 22: 1033-1043.
129. Papay P, Reinisch W, Ho E et al (2010). The impact of thiopurines on the risk of surgical recurrence in patients with Crohn' s Disease after first intestinal surgery. Am J Gastroenterol 105: 1158-1164.
130. Park H, Li Z, Yang XO et al (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
131. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W (2008). CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat Med 14: 528-535.
132. Pineton de Chambrun G, Columbel JF, Poulain D, Darfeuille-Michaud A (2008). Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 24: 440-447.
133. Plauth M, Jenss H, Meyle J (1991). Oral manifestations of Crohn's disease. An analysis of 79 cases. J Clin Gastroenterol 13: 29-37.
134. Potthast S, Rieber A, von Tirpitz C, Wruk D, Adler G, Brambs HJ (2002). Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 12: 1416-1422.
135. Prefontaine E, Sutherland LR, MacDonald JK (2009). Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 21: CD000545.
136. Prefontaine E, MacDonald JK, Sutherland LR (2010). Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 16: CD000545.
137. Qiao L, Schurmann G, Betzler M, Meuer SC (1991). Activation and signaling status of human lamina propria T lymphocytes. Gastroenterology 101: 1529-1536.
138. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB (2010). Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 59: 1200-1206.
139. Reimund JM, Wittersheim C, Dumont S et al (1996). Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 16: 144-150.
140. Reinecker HC, Steffen M, Witthoeft T et al (1993). Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174-181.
141. Rieber A, Aschoff A, Nussle K et al (2000). MRI in the diagnosis of small bowel disease: use of positive and negative oral contrast media in combination with enteroclysis. Eur Radiol 10: 1377-1382.
142. Rieber A, Nussle K, Reinshagen M, Brambs HJ, Gabelmann A (2002). MRI of the abdomen with positive oral contrast agents for the diagnosis of inflammatory small bowel disease. Abdom Imaging 27: 394-399.
143. Rimoldi M, Chieppa M, Salucci V et al (2005). Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 6: 507-514.
144. Rohr A, Rohr D, Kuhbacher T, Schreiber S, Heller M, Reuter M (2002). Radiological assessment of small bowel obstructions: value of conventional enteroclysis and dynamic MR-enteroclysis. Rofo 174: 1158-1164.
145. Rothfuss KS, Stange EF, Herrlinger KR (2006). Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 12: 4819-4831.
146. Round JL, Mazmanian SK (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9: 313-323.
147. Round JL, Mazmanian SK (2010). Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 107: 12204-12209.
148. Rovedatti L, Kudo T, Biancheri P et al (2009). Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 58: 1629-1636.
149. Rowland M, Fleming P, Bourke B (2010). Looking in the mouse for Crohn's disease. Inflamm Bowel Dis 16: 332-337.
150. Russel RK, Satsangi J (2004). IBD: a family affair. Best Pract Res Clin Gastroenterol 18: 525-539.
151. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M (1990). Predictability of the postoperative course of Crohn's disease. Gastroenterology 99: 956-963.
152. Rutgeerts P, Feagan BG, Lichtenstein GR et al (2004). Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402-413.
153. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005). Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476.
154. Rutter MD, Saunders BP, Wilkinson KH et al (2004). Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53: 1813-1816.
155. Rutter MD, Saunders BP, Wilkinson KH et al (2006). Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130: 1030-1038.
156. Sandborn WJ, Feagan BG, Hanauer SB et al (2002). A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122: 512-530.
157. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, American Gastroenterological Association Clinical Practice Committee (2003). AGA technical review on perianal Crohn's disease. Gastroenterology 125: 1508-1530.
158. Sandborn WJ, Feagan BG, Fedorak RN et al (2008). A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 135: 1130-1141.
159. Sands BE (2008). Fulminant colitis. J Gastrointest Surg 12: 2157-2159.
160. Sartor RB (2000). Antibiotics as therapeutic agents in Crohn's disease. In: Bayless TM, Hanauer S, eds Current Advanced Therapy of Inflammatory Bowel Disease. Hamilton: Decker Inc, pp. 359-362.
161. Saruta M, Yua QT, Fleshner PR et al (2007). Characterization of FOXP3+ CD4+ regulatory T cells in Crohn's disease. Clin Immunol 125: 281-290.
162. Saurer L, McCullough KC, Summerfield A (2007). In vitro induction of mucosa-type dendritic cells by all-trans retinoic acid. J Immunol 179: 3504-3514.
163. Scheper HJ, Brand HS (2002). Oral aspects of Crohn's disease. Int Dent J 52: 163-182.
164. Schwartz DA, Loftus EV Jr, Tremaine WJ et al (2002). The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122: 875-880.
165. Segal AW, Loewi G (1976). Neutrophil dysfunction in Crohn's disease. Lancet 2: 219-221.
166. Sellon RK, Tonkonogy S, Schultz M et al (1998). Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 5224-5231.
167. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE (2006). Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 4: 1017-1024.
168. Silverberg MS, Satsangi J, Ahmad T et al (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A): 5-36.
169. Smith PD, Smythies LE, Mosteller-Barnum M et al (2001). Intestinal macrophages lack CD14 and CD89 and consequently are downregulated for LPS- and IgA-mediated activities. J Immunol 167: 2651-2656.
170. Smith AM, Rahman FZ, Hayee B et al (2009). Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 206: 1883-1897.
171. Smythies LE, Sellers M, Clements RH et al (2005). Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75.
172. Sokol H, Pigneur B, Watterlot R et al (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105: 16731-16736.
173. Stange EF, Travis SP, Vermeire S et al (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 55(Suppl I): i1-i15.
174. Stange EF, Travis SP, Vermeire S et al (2008). European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2: 1-23.
175. Strober W, Fuss IJ, Blumberg RS (2002). The immunology of mucosal models of inflammation. Annu Rev Immunol 20: 495-549.
176. Strober W, Murray PJ, Kitani A, Watanabe T (2006). Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6: 9-20.
177. Swidsinski A, Ladho A, Pernthaler A et al (2002). Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54.
178. Thielman NM, Guerrant RL (2004). Clinical practice: acute infectious diarrhoea. N Engl J Med 350: 38-47.
179. Thomas PD, Forbes A, Green J et al (2003). Guidelines for the investigation of chronic diarrhoea, 2nd edition. Gut 52 (Suppl. 5): v1-v15.
180. Tiede I, Fritz G, Strand S et al (2003). CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111: 1133-1145.
181. Travassos LH, Carneiro LA, Ramjeet M et al (2010). Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 11: 55-62.
182. Travis SPL, Stange EF, Lémann M et al (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55(Suppl I): i16-i35.
183. Travis SPL, Stange EF, Lémann M et al (2008). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2: 24-62.
184. Valmori D, Raffina C, Raimbaud I, Ayyoub M (2010). Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+ Treg in the presence of lineage specific polarizing factors. Proc Natl Acad Sci USA 107: 19402-19407.
185. Van den Brande JM, Koehler TC, Zelinkova Z et al (2007). Prediction of anti tumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56: 509-517.
186. Velayos FS, Terdiman JP, Walsh JM (2005). Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345-1353.
187. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006). TGF-beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
188. Vermeire S, Wild G, Kocher K et al (2002). CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 71: 74-83.
189. Viennot S, Deleporte A, Moussata D, Nancey S, Flourié B, Reimund JM (2009). Colon cancer in inflammatory bowel disease: recent trends, questions and answers. Gastroenterol Clin Biol 33(Suppl 3): S190-S201.
190. Virgin HW, Levine B (2009). Autophagy genes in immunity. Nat Immunol 10: 461-470.
191. Volpe E, Servant N, Zollinger R et al (2008). A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)- 17 responses. Nat Immunol 9: 650-657.
192. Watanabe T, Kitani A, Murray PJ, Strober W (2004). NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5: 800-808.
193. Weersma RK, Stokkers PCF, van Bodegraven AA et al (2009). Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 58: 388-395.
194. Wellcome Trust Case Control Consortium (2007). Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 447: 661-678.
195. Williams LM, Rudensky AY (2007). Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8: 277-284.
196. Wing K, Fehervari Z, Sakaguchi S (2006). Emerging possibilities in the development and function of regulatory T cells. Int Immunol 18: 991-1000.
197. Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2003). Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125: 1576-1582.
198. Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004). Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2: 1088-1095.
199. Xu L, Kitani A, Fuss I, Strober W (2007). Cutting edge: regulatory T cells induce CD4+ CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 178: 6725-6729.
200. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H (2000). IL-6 is required for the development of TH1 cell-mediated murine colitis. J Immunol 164: 4878-4882.
201. Zaph C, Du Y, Saenz SA et al (2008). Commensal-dependent expression of IL-25 regulates the IL-23 - IL-17 axis in the intestine. J Exp Med 205: 2191-2198.
202. Zenewicz LA, Antov A, Flavell RA (2009). CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 15: 199-207.
203. Zhu J, Paul WE (2010). Heterogeneity and plasticity of T helper cells. Cell Res 20: 4-12.